Alzheimer's Type Dementia
Conditions
Keywords
Alzheimer Disease, Dementia, Delirium, Amnestic, Cognitive Disorders, Donepezil, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders, Cholinesterase Inhibitors, Enzy
Brief summary
The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.
Interventions
DRUGE2020
In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
DRUGPlacebo
Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
Sponsors
Eisai Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent (IC) will be obtained from the subject (if possible) or from the subject's legal guardian or legal representative prior to beginning screening activities. * Subject age range: male and female subjects 50 to 90 years of age, inclusive * Diagnosis: diagnostic evidence of probable Alzheimer's Disease (AD) consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria * MMSE 1 to 12 inclusive, at both Screening and Baseline * SIB less than or equal to 90 and greater than or equal to 10 at both Screening and Baseline * Comorbid medical conditions must be clinically stable prior to Baseline, unless otherwise specified.
Exclusion criteria
* Subjects with a known history of disorders that affect cognition or the ability to assess cognition, but are distinguishable from AD * Evidence of focal disease to account for dementia on any cranial image MRI or CT. * Subjects with dementia complicated by other organic disease or AD with delirium according to DSM-IV criteria * Subjects who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed * Illiteracy prior to AD * Subjects who are unwilling or unable to fulfill the requirements of the study * Treatment with another cholinesterase inhibitor and/or memantine in the 3 months prior to Screening * Subjects with a poor response (tolerability) to prior exposure to donepezil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in the total Severe Impairment Battery (SIB) score at Week 24 | 24 weeks | All statistical tests will be conducted at the 0.05 level of significance (two-tailed). A positive outcome will be declared if for the primary efficacy endpoint as measured by the Severe Impairment Battery (SIB), the change from Baseline to Week 24 in the total SIB score last observation carried forward (LOCF) demonstrates superiority for donepezil 10 mg, compared with placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinician Interview-Based Impression of Severity (CIBIC)+ overall score at Week 24 | 24 weeks | An ANCOVA with embedded Cochran-Mantel-Haenszel (CMH) test will be used with the CIBIC+ and center in the model. Overall change from Baseline in scores at Week 24 (LOCF) will be analyzed with the same model as the SIB. |
Countries
China
Outcome results
None listed